drugset / Trial / NCT00840866

Cefprozil 500 mg Tablets Under Fed Conditions

NCT00840866

Phase 1 Completed 39 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets with that of Cefzil 500 mg tablets in healthy, non-smoking adults under non-fasting conditions.

Timeline

Start
2003-09
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CEFPROZIL ANHYDROUS, (E)- Small molecule 500 mg

Indications

No indication recorded.